The abstract is read at the publisher; the summary is JClub's.
In the eSMARTER decentralized remote noninferiority trial, digital return of APOE genotype is noninferior to clinician-mediated telehealth for 1–7 day AD knowledge and psychological outcomes.
- Why it matters: As more patients receive Alzheimer disease genetic and biomarker information via electronic portals, scalable delivery models are needed that preserve knowledge and psychological well-being.
- What they did: Adults aged 60–80 who had undisclosed APOE genotyping via GeneMatch were randomized 2:1 to the eSMARTER digital platform (n=435) or clinician-mediated return (n=216), with primary outcomes assessed 1–7 days after disclosure.
- The result: AD-related knowledge, Patient-Reported Outcomes Measurement Information System Anxiety T-score, and disease-specific distress met noninferiority, and no significant between-group differences were found after optional p-tau217 disclosure.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.